RxMapper is a promising player in the intersection of Biotechnology and Health Care, leveraging cutting-edge technology to enhance patient health and economic outcomes. Founded in 2018 and headquartered in the United States, the company offers a novel solution in personalized medication monitoring and telehealth consultations, developed in collaboration with Mayo Clinic.
The platform employs DNA sequencing analysis to provide pharmacists with precise drug compatibility advice for each patient, a feature that potentially reduces healthcare costs and improves patient outcomes. Notably, this approach serves not only individual patients but also provides broad implications for Health Insurance and Human Resources sectors.
RxMapper secured a Seed Round investment on 01 November 2022, suggesting strong initial interest and financial backing, but the specifics of the investment remain undisclosed. With its innovative model and strategic partnerships, RxMapper is well-positioned for growth in the personalized medicine sector.